Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: Insights from experimental heart failure

Horng Haur Chen, Alessandro Cataliotti, John C Jr. Burnett

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Vasopeptidase (VP) inhibitors are novel molecules that coinhibit neutral endopeptidase 24.11 (NEP), which degrades natriuretic peptides and angiotensin-converting enzyme (ACE). We review the biology of the natriuretic peptide system and a recent study of the role for the natriuretic peptide system in the mechanism of action of omapatrilat (the most clinically advanced VP inhibitor). This study compared the cardiorenal and humoral actions of omapatrilat with those of ACE inhibition. The actions of omapatrilat were further defined in the presence and absence of a natriuretic peptide receptor antagonist. This investigation provided insight into a unique new pharmacologic agent that has beneficial renal actions in experimental mild heart failure that exceed those seen with ACE inhibition alone and that are linked to the natriuretic peptide system.

Original languageEnglish (US)
JournalCurrent Hypertension Reports
Volume3
Issue numberSUPPL. 2
DOIs
StatePublished - 2001

Fingerprint

Natriuretic Peptides
Heart Failure
Peptidyl-Dipeptidase A
Neprilysin
Peptide Receptors
omapatrilat
Kidney

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{aca9b8952f7f43d58131cc826cde7200,
title = "Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: Insights from experimental heart failure",
abstract = "Vasopeptidase (VP) inhibitors are novel molecules that coinhibit neutral endopeptidase 24.11 (NEP), which degrades natriuretic peptides and angiotensin-converting enzyme (ACE). We review the biology of the natriuretic peptide system and a recent study of the role for the natriuretic peptide system in the mechanism of action of omapatrilat (the most clinically advanced VP inhibitor). This study compared the cardiorenal and humoral actions of omapatrilat with those of ACE inhibition. The actions of omapatrilat were further defined in the presence and absence of a natriuretic peptide receptor antagonist. This investigation provided insight into a unique new pharmacologic agent that has beneficial renal actions in experimental mild heart failure that exceed those seen with ACE inhibition alone and that are linked to the natriuretic peptide system.",
author = "Chen, {Horng Haur} and Alessandro Cataliotti and Burnett, {John C Jr.}",
year = "2001",
doi = "10.1007/s11906-001-0102-y",
language = "English (US)",
volume = "3",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat

T2 - Insights from experimental heart failure

AU - Chen, Horng Haur

AU - Cataliotti, Alessandro

AU - Burnett, John C Jr.

PY - 2001

Y1 - 2001

N2 - Vasopeptidase (VP) inhibitors are novel molecules that coinhibit neutral endopeptidase 24.11 (NEP), which degrades natriuretic peptides and angiotensin-converting enzyme (ACE). We review the biology of the natriuretic peptide system and a recent study of the role for the natriuretic peptide system in the mechanism of action of omapatrilat (the most clinically advanced VP inhibitor). This study compared the cardiorenal and humoral actions of omapatrilat with those of ACE inhibition. The actions of omapatrilat were further defined in the presence and absence of a natriuretic peptide receptor antagonist. This investigation provided insight into a unique new pharmacologic agent that has beneficial renal actions in experimental mild heart failure that exceed those seen with ACE inhibition alone and that are linked to the natriuretic peptide system.

AB - Vasopeptidase (VP) inhibitors are novel molecules that coinhibit neutral endopeptidase 24.11 (NEP), which degrades natriuretic peptides and angiotensin-converting enzyme (ACE). We review the biology of the natriuretic peptide system and a recent study of the role for the natriuretic peptide system in the mechanism of action of omapatrilat (the most clinically advanced VP inhibitor). This study compared the cardiorenal and humoral actions of omapatrilat with those of ACE inhibition. The actions of omapatrilat were further defined in the presence and absence of a natriuretic peptide receptor antagonist. This investigation provided insight into a unique new pharmacologic agent that has beneficial renal actions in experimental mild heart failure that exceed those seen with ACE inhibition alone and that are linked to the natriuretic peptide system.

UR - http://www.scopus.com/inward/record.url?scp=0035656143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035656143&partnerID=8YFLogxK

U2 - 10.1007/s11906-001-0102-y

DO - 10.1007/s11906-001-0102-y

M3 - Article

C2 - 11716801

AN - SCOPUS:0035656143

VL - 3

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - SUPPL. 2

ER -